Dance Biopharm announces completion of $9.5 million convertible note and warrants financing

Dance Biopharm Inc., a privately-held biotechnology company focused on the development of inhaled insulin products to treat diabetes, today announced the completion of a $9.5 million convertible note and warrants financing.



from The Medical News http://ift.tt/1G69XzD